Amylin Pharmaceuticals and Takeda Pharmaceutical have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize compounds for the treatment of obesity and related indications. The agreement includes Amylin’s pramlintide/metreleptin and davalintide, which are currently in Phase II development for treatment of obesity. The agreement also includes additional compounds from both companies’ obesity research programs. Amylin ...